Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Revvity is moving to deepen its position in human-relevant drug discovery with the planned acquisition of France-based Human Cell Design, a biotechnology company specializing in human cell models for diabetes, obesity, and other metabolic diseases.</li><li>Announced on September 9, 2026, the transaction is expected to close in the fourth quarter of 2026, subject to regulatory approvals and customary conditions, while financial terms remain undisclosed.</li><li>The acquisition would add Human Cell Design’s pancreatic beta cell models to Revvity’s Life Sciences portfolio, extending its capabilities in GLP-1 and broader metabolic drug screening while creating potential applications in regenerative medicine and cell-based therapies.</li></ul>

Revvity is moving to deepen its position in human-relevant drug discovery with the planned acquisition of France-based Human Cell Design, a biotechnology company specializing in human cell models for diabetes, obesity, and other metabolic diseases.Announced on September 9, 2026, the transaction is expected to close in the fourth quarter of 2026, subject to regulatory approvals and customary conditions, while financial terms remain undisclosed.The acquisition would add Human Cell Design’s pancreatic beta cell models to Revvity’s Life Sciences portfolio, extending its capabilities in GLP-1 and broader metabolic drug screening while creating potential applications in regenerative medicine and cell-based therapies.

Revvity’s Human Cell Design Takeover Could Reshape Discovery!

<ul><li>Revvity reported solid financial and operational results for the second quarter of 2026, with total revenue of $711 million and pro forma organic growth of 3%, slightly surpassing the high end of company guidance.</li><li>The diagnostics segment was a key driver of this growth, delivering an 11% organic increase, supported by strong performance in immunodiagnostics outside China and reproductive health sectors, including ongoing contributions from the Genomics England sequencing contract.</li><li>Conversely, the Life Sciences segment experienced a 3% organic decline primarily due to a roughly 20% year-over-year drop in the Signals software business, attributed to contract timing and challenging year-ago comparisons.</li></ul>

Revvity reported solid financial and operational results for the second quarter of 2026, with total revenue of $711 million and pro forma organic growth of 3%, slightly surpassing the high end of company guidance.The diagnostics segment was a key driver of this growth, delivering an 11% organic increase, supported by strong performance in immunodiagnostics outside China and reproductive health sectors, including ongoing contributions from the Genomics England sequencing contract.Conversely, the Life Sciences segment experienced a 3% organic decline primarily due to a roughly 20% year-over-year drop in the Signals software business, attributed to contract timing and challenging year-ago comparisons.

Revvity’s Strategic Shift — China Exit & AI Investment Reshape The Portfolio!

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

iShares PHLX Semiconductor ETF / Technical Analysis

<ul>
<li>We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), and we will stay that way as long as support at 7507-7580 holds.</li>
<li>We continue to believe Technology and A.I. areas (XLK, SOXX, DRAM) are poised to move higher, and we have Technology on watch for a potential upgrade to overweight.</li>
<li>A significant "wall of worry" is being built, with the latest bricks being bad breadth and rising interest rate volatility</li>
</ul>


We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), and we will stay that way as long as support at 7507-7580 holds.
We continue to believe Technology and A.I. areas (XLK, SOXX, DRAM) are poised to move higher, and we have Technology on watch for a potential upgrade to overweight.
A significant "wall of worry" is being built, with the latest bricks being bad breadth and rising interest rate volatility


Interest Rate Volatility, High Yield Spreads, and Bad Breadth a Concern? All Hinges on 7507-7580 SPX

<ul><li>Revvity reported first quarter 2026 results demonstrating 3% total company organic growth alongside adjusted operating margins of 23.6%, exceeding their earlier outlook.</li><li>Adjusted earnings per share came in at $1.06, surpassing guidance by a modest margin.</li><li>The company’s Life Sciences segment grew 3% organically, driven by low single-digit growth in reagents and mid-single-digit growth in instrumentation, while the Diagnostics segment grew 4% organically, bolstered by strong double-digit growth in Reproductive Health and stable performance in Immunodiagnostics outside China.</li></ul>

Revvity reported first quarter 2026 results demonstrating 3% total company organic growth alongside adjusted operating margins of 23.6%, exceeding their earlier outlook.Adjusted earnings per share came in at $1.06, surpassing guidance by a modest margin.The company’s Life Sciences segment grew 3% organically, driven by low single-digit growth in reagents and mid-single-digit growth in instrumentation, while the Diagnostics segment grew 4% organically, bolstered by strong double-digit growth in Reproductive Health and stable performance in Immunodiagnostics outside China.

Revvity: From China Exit to SaaS Momentum—A Strategic Reset Taking Shape!

<ul><li>Revvity shares surged over 9% after the health-sciences company raised its 2025 earnings per share outlook above $5.00 and boosted Q4 revenue guidance to $772 million, exceeding Wall Street expectations.</li><li>The company’s preliminary results, released ahead of its presentation at the JPMorgan Healthcare Conference, came as a surprise to a market that had seen RVTY down 9% over the past 12 months.</li><li>Yet, despite the better-than-expected guidance and a solid 2026 margin outlook, investor sentiment remains cautious.</li></ul>

Revvity shares surged over 9% after the health-sciences company raised its 2025 earnings per share outlook above $5.00 and boosted Q4 revenue guidance to $772 million, exceeding Wall Street expectations.The company’s preliminary results, released ahead of its presentation at the JPMorgan Healthcare Conference, came as a surprise to a market that had seen RVTY down 9% over the past 12 months.Yet, despite the better-than-expected guidance and a solid 2026 margin outlook, investor sentiment remains cautious.

Revvity Popped On Earnings Boost—Will Feb. 2 Spark The Next Big Move?

United States

Revvity, Inc. provides health science solutions, technologies, expertise, and services. The Company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics, and other areas. Revvity serves pharmaceutical and biotech, clinical labs, academia, and governments worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Revvity (RVTY US)

Revvity’s Human Cell Design Takeover Could Reshape Discovery!

Revvity is moving to deepen its position in human-relevant drug discovery with the planned acquisition of France-based Human Cell Design, a...

Baptista Research

Revvity’s Strategic Shift — China Exit & AI Investment Reshape The Portfolio!

Revvity reported solid financial and operational results for the second quarter of 2026, with total revenue of $711 million and pro forma organic...

Baptista Research

Interest Rate Volatility, High Yield Spreads, and Bad Breadth a Concern? All Hinges on 7507-7580 SPX

Interest Rate Volatility, High Yield Spreads, and Bad Breadth a Concern?; All Hinges on 7507-7580 $SPX. We continue to believe Technology and A.I....

Vermilion Research

Revvity: From China Exit to SaaS Momentum—A Strategic Reset Taking Shape!

Revvity reported first quarter 2026 results demonstrating 3% total company organic growth alongside adjusted operating margins of 23.6%, exceeding...

Baptista Research

Revvity Popped On Earnings Boost—Will Feb. 2 Spark The Next Big Move?

Revvity shares surged over 9% after the health-sciences company raised its 2025 earnings per share outlook above $5.00 and boosted Q4 revenue...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)